Explore

Trendline Trendline
Fosun Pharma and AriBio Sign Agreement for Alzheimer's Drug Development

Fosun Pharma and AriBio Sign Agreement for Alzheimer's Drug Development

Fosun Pharma and AriBio Sign Agreement for Alzheimer's Drug Development
Trendline Trendline
Kariya Pharmaceuticals and NeuraLight Collaborate on Brain-Focused GLP-1 Therapeutics for Neurodegenerative Diseases

Kariya Pharmaceuticals and NeuraLight Collaborate on Brain-Focused GLP-1 Therapeutics for Neurodegenerative Diseases

Kariya Pharmaceuticals and NeuraLight Collaborate on Brain-Focused GLP-1 Therapeutics for Neurodegenerative Diseases
Trendline Trendline
Kariya and NeuraLight Collaborate on Brain-Focused GLP-1 Therapies for Neurodegenerative Diseases

Kariya and NeuraLight Collaborate on Brain-Focused GLP-1 Therapies for Neurodegenerative Diseases

Kariya and NeuraLight Collaborate on Brain-Focused GLP-1 Therapies for Neurodegenerative Diseases
Trendline Trendline
BridgeBio's Attruby Shows Potential Superiority Over Pfizer's Tafamidis in ATTR-CM Survival Rates

BridgeBio's Attruby Shows Potential Superiority Over Pfizer's Tafamidis in ATTR-CM Survival Rates

BridgeBio's Attruby Shows Potential Superiority Over Pfizer's Tafamidis in ATTR-CM Survival Rates
Trendline Trendline
Biogen Advances Alzheimer's Drug Diranersen Despite Phase 2 Trial Setback

Biogen Advances Alzheimer's Drug Diranersen Despite Phase 2 Trial Setback

Biogen Advances Alzheimer's Drug Diranersen Despite Phase 2 Trial Setback
Trendline Trendline
AstraZeneca's Hypoparathyroidism Drug Faces Efficacy Questions Amid Rivalry

AstraZeneca's Hypoparathyroidism Drug Faces Efficacy Questions Amid Rivalry

AstraZeneca's Hypoparathyroidism Drug Faces Efficacy Questions Amid Rivalry
Trendline Trendline
Palatin Technologies Advances Obesity Treatments with MC4R Agonists

Palatin Technologies Advances Obesity Treatments with MC4R Agonists

Palatin Technologies Advances Obesity Treatments with MC4R Agonists
Trendline Trendline
Immunome Advances Oncology Pipeline with New Drug Application and Clinical Trials

Immunome Advances Oncology Pipeline with New Drug Application and Clinical Trials

Immunome Advances Oncology Pipeline with New Drug Application and Clinical Trials
Trendline Trendline
Tempus and Bristol Myers Squibb Collaborate to Enhance Clinical Trials with AI

Tempus and Bristol Myers Squibb Collaborate to Enhance Clinical Trials with AI

Tempus and Bristol Myers Squibb Collaborate to Enhance Clinical Trials with AI
Trendline Trendline
Lysoway Therapeutics Begins Phase I Trial of TRPML1 Agonist for Neurodegenerative Diseases

Lysoway Therapeutics Begins Phase I Trial of TRPML1 Agonist for Neurodegenerative Diseases

Lysoway Therapeutics Begins Phase I Trial of TRPML1 Agonist for Neurodegenerative Diseases
Trendline Trendline
Cellular Intelligence Acquires Novo Nordisk's Parkinson's Therapy to Advance Clinical Development

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Therapy to Advance Clinical Development

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Therapy to Advance Clinical Development
Trendline Trendline
AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials

AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials

AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials